Breaking News, Financial News

Financial Report: Genzyme 4Q

Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption.

Genzyme 4Q

4Q Revenues: $1.1 billion (-8%)

4Q Earnings: $23.2 million (earnings were $86.7 million in 4Q08)

FY Revenues: $4.5 billion (-2%)

FY Revenues: $422.3 million (flat)

Comments: Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption. Cerezyme sales were $105.4 million (-66%), and Fabrazyme sales were down 54% to $58.0 million. Cardiometabolic and Renal sales in the quarter were $259.2 million (+7%). Renagel and Renvela sales were $178.9 million (+6%). Hematologic Oncology revenue was $108.3 million in the quarter (+154%). R&D expenses were down 36% in the quarter to $228.5 million.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters